Phaseline

Targets › MYH7

MYH7 (Myosin-7): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 4 Phase 3, 2 Phase 4, 1 Phase 2; Cardiovascular; next expected readout Jun 2027.

Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. (UniProt, P12883)

Open in Phaseline: the race on MYH7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbMavacamten (BMS-986427)
Cardiac myosin inhibitor
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 4Cardiomyopathy, Hypertrophic; Symptomatic Obstructive Hypertrophic CardiomyopathyJun 2027
CytokineticsOmecamtiv Mecarbil
Cardiac myosin activator
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 3Heart FailureSep 2027
Kardigandanicamtiv
Cardiac myosin activator
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 3Symptomatic Genetic Dilated Cardiomyopathy (DCM); Symptomatic Genetic Dilated CardiomyopathySep 2027
BayerAficamten (BAY3723113, CK-3773274)
Cardiac myosin inhibitor
MYH7Phase 3Obstructive Hypertrophic CardiomyopathyMay 2028

Conditions

Cardiomyopathy, Hypertrophic (2) Obstructive Hypertrophic Cardiomyopathy (1) Symptomatic Obstructive Hypertrophic Cardiomyopathy (1) Symptomatic Genetic Dilated Cardiomyopathy (DCM) (1) Symptomatic Genetic Dilated Cardiomyopathy (1) Heart Failure (1)

Modalities

small molecule (4)

Companies

Bayer (1) Bristol-Myers Squibb (1) Kardigan (1) Cytokinetics (1)

Related targets

MYH6 (3) MYH7B (3) MYL3 (3) MYL2 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.